Table 1.
Patient and disease characteristics at baseline
| Evaluable patients (n = 77) n (%) |
||
|---|---|---|
| Age at study entry (years) | Median (range) | 66.0 (40.0–78.0) |
| Tumor location at initial diagnosis | Ovary | 68 (88.3) |
| Tubes | 5 (6.5) | |
| Peritoneum | 4 (5.2) | |
| Histopathology | Serous | 54 (70.1) |
| Endometrioid | 6 (7.8) | |
| Other/unknown | 17 (22.1) | |
| Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis | IC | 2 (2.6) |
| IIIA | 3 (3.9) | |
| IIIB | 8 (10.4) | |
| IIIC | 38 (49.4) | |
| IV | 15 (19.5) | |
| Unknown | 11 (14.3) | |
| Platinum-free interval (months) | Median (range) | 12 (6–86) |
| Eastern Cooperative Oncology Group (ECOG) performance status | 0 | 29 (37.7) |
| 1 | 33 (42.9) | |
| 0–1 | 62 (80.5) | |
| 2 | 2 (2.6) | |
| Not available | 13 (16.9) | |
| Prior treatments | Prior surgery | 77 (100) |
| Complete resection | 20 (26.0) | |
| Residual tumor ≤ 1 cm | 11 (14.3) | |
| Residual tumor > 1 cm | 16 (20.8) | |
| Unknown residual tumor | 30 (39.0) | |
| Prior secondary surgery | 18 (23.4) | |
| Complete resection | 4 (5.2) | |
| Residual tumor ≤ 1 cm | 2 (2.6) | |
| Residual tumor > 1 cm | 3 (3.9) | |
| Unknown residual tumor | 9 (11.7) | |
| Prior radiotherapy | 3 (3.9) | |
| Prior chemotherapy | 77 (100) | |
| No. of chemotherapy lines prior to trabectedin plus pegylated liposomal doxorubicin (PLD) | Median (range) | 2.0 (1–6) |
| One prior line | 26 (33.8) | |
| Two prior lines | 33 (42.9) | |
| Three prior lines | 12 (15.6) | |
| Four prior lines | 5 (6.4) | |
| Six prior lines | 1 (1.3) | |
| Response to last chemotherapy | Complete response (CR) | 23 (29.9) |
| Partial response (PR) | 25 (32.5) | |
| Stable disease (SD) | 16 (20.8) | |
| Progressive disease (PD) | 8 (10.4) | |
| Non evaluated (NE) | 5 (6.5) | |